Cite
Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer.
MLA
Goode, Ellen L., et al. “Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer.” JAMA Oncology, vol. 3, no. 12, Dec. 2017, p. e173290. EBSCOhost, https://doi.org/10.1001/jamaoncol.2017.3290.
APA
Goode, E. L., Block, M. S., Kalli, K. R., Vierkant, R. A., Chen, W., Fogarty, Z. C., Gentry-Maharaj, A., Tołoczko, A., Hein, A., Bouligny, A. L., Jensen, A., Osorio, A., Hartkopf, A., Ryan, A., Chudecka-Głaz, A., Magliocco, A. M., Hartmann, A., Jung, A. Y., Gao, B., … Ramus, S. J. (2017). Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer. JAMA Oncology, 3(12), e173290. https://doi.org/10.1001/jamaoncol.2017.3290
Chicago
Goode, Ellen L, Matthew S Block, Kimberly R Kalli, Robert A Vierkant, Wenqian Chen, Zachary C Fogarty, Aleksandra Gentry-Maharaj, et al. 2017. “Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer.” JAMA Oncology 3 (12): e173290. doi:10.1001/jamaoncol.2017.3290.